0
By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.
Don’t have an account? Signup
Powered by :
Jubilant Pharmova reports Q3 FY26 revenue of Rs 2,123 crore and EBITDA of Rs 310 crore, driven by growth in CDMO, radiopharma, and generics businesses.
Share this article
If you liked this article share it with your friends.they will thank you later